How can sentinel navigation surgery abbreviate mediastinal lymph node dissection for lung cancer?

Hiroaki Nomori, Takashi Ohtsuka, Tsuguo Naruke, Keiichi Suemasu

Research output: Contribution to journalArticle

Abstract

Sentinel nodes (SNs) were examined for 101 patients who had peripheral type non-small cell lung cancer less than 5 cm and had undergone systemic mediastinal lymph node dissection. The surgical procedure was lobectomy in 91, pneumonectomy in 3, and segmentectomy with lymph node dissection in 7. In the CT room, the site for RI injection was marked on the skin, and the angle and depth of the needle required to reach the peritumoral region was determined. The RI was then injected in the RI room. The radioactivity in the lymph nodes was counted before dissection (in vivo counting), and after dissection that (ex vivo counting). SNs were defined as any node for which the count was > or = 10 times than the background count. SN identification was finally based on ex vivo data. Of the 101 patients, SNs could be identified in 80 patients (80%). Patients whose SNs could not be identified had a significantly lower FEV1/FVC than those with identifiable SNs (p=0.025). Twenty six patients (33%) had SN in the mediastinum, the distribution of which depended on the lobe, ie the #4 lymph node station in the right upper lobe, the #4 in the right middle lobe, the #4 and 7 in the right lower lobe, the #5 in the left upper lobe, and the #7 in the left lower lobe. One false negative SN was detected in 25 patients with N 1 or N 2 disease (4%). In vivo and ex vivo counting showed 73% concurrence for the identification of SNs in mediastinal lymph node stations, of which rate was significantly higher than 40% in hilar lymph node stations (p<0.001). Conclusion: The SNs were identifiable in 80% of lung cancer patients, with 4% false negative by using a Tc-99 m tin-colloid. SNs were difficult to identify in patients with a low level of FEV1/FVC, such as those with chronic obstructive pulmonary disease. The in vivo identification of mediastinal SNs was reliable as much as the ex vivo. Therefore, the in vivo identification of SNs in the mediastinum could be useful approach to guide mediastinal lymph node sampling or dissection.

Original languageEnglish
Pages (from-to)1125-1129
Number of pages5
JournalGan to kagaku ryoho. Cancer & chemotherapy
Volume31
Issue number7
Publication statusPublished - 2004 Jul
Externally publishedYes

Fingerprint

Lymph Node Excision
Lung Neoplasms
Lymph Nodes
Dissection
Mediastinum
cyhalothrin
Segmental Mastectomy
Pneumonectomy
Tin
Colloids
Non-Small Cell Lung Carcinoma
Radioactivity
Chronic Obstructive Pulmonary Disease
Needles

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology

Cite this

How can sentinel navigation surgery abbreviate mediastinal lymph node dissection for lung cancer? / Nomori, Hiroaki; Ohtsuka, Takashi; Naruke, Tsuguo; Suemasu, Keiichi.

In: Gan to kagaku ryoho. Cancer & chemotherapy, Vol. 31, No. 7, 07.2004, p. 1125-1129.

Research output: Contribution to journalArticle

Nomori, Hiroaki ; Ohtsuka, Takashi ; Naruke, Tsuguo ; Suemasu, Keiichi. / How can sentinel navigation surgery abbreviate mediastinal lymph node dissection for lung cancer?. In: Gan to kagaku ryoho. Cancer & chemotherapy. 2004 ; Vol. 31, No. 7. pp. 1125-1129.
@article{e6be82f0ba0e4b20a19997df85d90e3e,
title = "How can sentinel navigation surgery abbreviate mediastinal lymph node dissection for lung cancer?",
abstract = "Sentinel nodes (SNs) were examined for 101 patients who had peripheral type non-small cell lung cancer less than 5 cm and had undergone systemic mediastinal lymph node dissection. The surgical procedure was lobectomy in 91, pneumonectomy in 3, and segmentectomy with lymph node dissection in 7. In the CT room, the site for RI injection was marked on the skin, and the angle and depth of the needle required to reach the peritumoral region was determined. The RI was then injected in the RI room. The radioactivity in the lymph nodes was counted before dissection (in vivo counting), and after dissection that (ex vivo counting). SNs were defined as any node for which the count was > or = 10 times than the background count. SN identification was finally based on ex vivo data. Of the 101 patients, SNs could be identified in 80 patients (80{\%}). Patients whose SNs could not be identified had a significantly lower FEV1/FVC than those with identifiable SNs (p=0.025). Twenty six patients (33{\%}) had SN in the mediastinum, the distribution of which depended on the lobe, ie the #4 lymph node station in the right upper lobe, the #4 in the right middle lobe, the #4 and 7 in the right lower lobe, the #5 in the left upper lobe, and the #7 in the left lower lobe. One false negative SN was detected in 25 patients with N 1 or N 2 disease (4{\%}). In vivo and ex vivo counting showed 73{\%} concurrence for the identification of SNs in mediastinal lymph node stations, of which rate was significantly higher than 40{\%} in hilar lymph node stations (p<0.001). Conclusion: The SNs were identifiable in 80{\%} of lung cancer patients, with 4{\%} false negative by using a Tc-99 m tin-colloid. SNs were difficult to identify in patients with a low level of FEV1/FVC, such as those with chronic obstructive pulmonary disease. The in vivo identification of mediastinal SNs was reliable as much as the ex vivo. Therefore, the in vivo identification of SNs in the mediastinum could be useful approach to guide mediastinal lymph node sampling or dissection.",
author = "Hiroaki Nomori and Takashi Ohtsuka and Tsuguo Naruke and Keiichi Suemasu",
year = "2004",
month = "7",
language = "English",
volume = "31",
pages = "1125--1129",
journal = "Japanese Journal of Cancer and Chemotherapy",
issn = "0385-0684",
publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",
number = "7",

}

TY - JOUR

T1 - How can sentinel navigation surgery abbreviate mediastinal lymph node dissection for lung cancer?

AU - Nomori, Hiroaki

AU - Ohtsuka, Takashi

AU - Naruke, Tsuguo

AU - Suemasu, Keiichi

PY - 2004/7

Y1 - 2004/7

N2 - Sentinel nodes (SNs) were examined for 101 patients who had peripheral type non-small cell lung cancer less than 5 cm and had undergone systemic mediastinal lymph node dissection. The surgical procedure was lobectomy in 91, pneumonectomy in 3, and segmentectomy with lymph node dissection in 7. In the CT room, the site for RI injection was marked on the skin, and the angle and depth of the needle required to reach the peritumoral region was determined. The RI was then injected in the RI room. The radioactivity in the lymph nodes was counted before dissection (in vivo counting), and after dissection that (ex vivo counting). SNs were defined as any node for which the count was > or = 10 times than the background count. SN identification was finally based on ex vivo data. Of the 101 patients, SNs could be identified in 80 patients (80%). Patients whose SNs could not be identified had a significantly lower FEV1/FVC than those with identifiable SNs (p=0.025). Twenty six patients (33%) had SN in the mediastinum, the distribution of which depended on the lobe, ie the #4 lymph node station in the right upper lobe, the #4 in the right middle lobe, the #4 and 7 in the right lower lobe, the #5 in the left upper lobe, and the #7 in the left lower lobe. One false negative SN was detected in 25 patients with N 1 or N 2 disease (4%). In vivo and ex vivo counting showed 73% concurrence for the identification of SNs in mediastinal lymph node stations, of which rate was significantly higher than 40% in hilar lymph node stations (p<0.001). Conclusion: The SNs were identifiable in 80% of lung cancer patients, with 4% false negative by using a Tc-99 m tin-colloid. SNs were difficult to identify in patients with a low level of FEV1/FVC, such as those with chronic obstructive pulmonary disease. The in vivo identification of mediastinal SNs was reliable as much as the ex vivo. Therefore, the in vivo identification of SNs in the mediastinum could be useful approach to guide mediastinal lymph node sampling or dissection.

AB - Sentinel nodes (SNs) were examined for 101 patients who had peripheral type non-small cell lung cancer less than 5 cm and had undergone systemic mediastinal lymph node dissection. The surgical procedure was lobectomy in 91, pneumonectomy in 3, and segmentectomy with lymph node dissection in 7. In the CT room, the site for RI injection was marked on the skin, and the angle and depth of the needle required to reach the peritumoral region was determined. The RI was then injected in the RI room. The radioactivity in the lymph nodes was counted before dissection (in vivo counting), and after dissection that (ex vivo counting). SNs were defined as any node for which the count was > or = 10 times than the background count. SN identification was finally based on ex vivo data. Of the 101 patients, SNs could be identified in 80 patients (80%). Patients whose SNs could not be identified had a significantly lower FEV1/FVC than those with identifiable SNs (p=0.025). Twenty six patients (33%) had SN in the mediastinum, the distribution of which depended on the lobe, ie the #4 lymph node station in the right upper lobe, the #4 in the right middle lobe, the #4 and 7 in the right lower lobe, the #5 in the left upper lobe, and the #7 in the left lower lobe. One false negative SN was detected in 25 patients with N 1 or N 2 disease (4%). In vivo and ex vivo counting showed 73% concurrence for the identification of SNs in mediastinal lymph node stations, of which rate was significantly higher than 40% in hilar lymph node stations (p<0.001). Conclusion: The SNs were identifiable in 80% of lung cancer patients, with 4% false negative by using a Tc-99 m tin-colloid. SNs were difficult to identify in patients with a low level of FEV1/FVC, such as those with chronic obstructive pulmonary disease. The in vivo identification of mediastinal SNs was reliable as much as the ex vivo. Therefore, the in vivo identification of SNs in the mediastinum could be useful approach to guide mediastinal lymph node sampling or dissection.

UR - http://www.scopus.com/inward/record.url?scp=3242702317&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3242702317&partnerID=8YFLogxK

M3 - Article

VL - 31

SP - 1125

EP - 1129

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

SN - 0385-0684

IS - 7

ER -